RPRX vs RVMD: Which Stock Is the Better Buy?
Royalty Pharma plc and Revolution Medicines, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RPRX vs RVMD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Royalty Pharma plc (RPRX) | Revolution Medicines, Inc. (RVMD) | |
|---|---|---|
| Market cap | $31.6B | $31.3B |
| Revenue (latest FY) | $2.38B | $0 |
| Net income (latest FY) | $770.95M | $-1.13B |
| Revenue growth (5y CAGR) | 2.3% | — |
| Net margin | 32.4% | — |
| Return on equity | 11.9% | -69.3% |
| P/E ratio | 28.9 | — |
| Dividend yield | 1.7% | — |
| Profitable years (of last 10) | 8 | 0 |
| Positive free cash flow | — | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full RPRX vs RVMD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RPRX's full financials → Open RVMD's full financials →More comparisons
Frequently asked questions
Which is bigger, RPRX or RVMD?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $31.3B.
Which grows faster, RPRX or RVMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
RPRX fundamentals → · RVMD fundamentals → · All 1,500+ companies → · Free screener →